The US blister packaging market is estimated to grow at a CAGR of 4.9% during the forecast period. The market growth is attributed to the presence of well-established biopharmaceutical industry in the country. North America is considered among the most developed markets for diabetes treatment, as there are numerous companies and research institutes focused on the R&D regarding drug development and manufacturing.
In addition, according to International Diabetes Federation, in 2019, the prevalence of diabetes is around 13.3% of the total adult population in the region which is expected to increase up to 14.2% by 2030 and 15% by 2045. With the increasing prevalence of diabetes, the demand for drugs increases and to meet the growing demand, the manufacturers are trying their best to get approval from FDA to bring their products to the market.
Browse the full report description of "US Blister Market Size, Share & Trends Analysis Report by Process (Thermoforming Blister Pack and Cold Forming Blister Pack), By Application (Consumer Goods, Pharmaceutical, Food, and Others) Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/us-blister-market
For instance, in August 2015, Synjardy (empagliflozin and metformin hydrochloride) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co. was approved by the FDA for the treatment of adults with type 2 diabetes (T2D). SYNJARDY is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin). With the new tablets coming into the market, the demand for blister packaging increases. Thus, the increased prevalence of diabetes provides growth opportunities for the US blister packaging industry during the forecast period.
Market Coverage
Key Questions Addressed by the Report
US Blister Packaging Market – Segmentation
By Process
By Application
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/us-blister-market